4.3 Review

The Common Cold: Potential for Future Prevention or Cure

期刊

CURRENT ALLERGY AND ASTHMA REPORTS
卷 14, 期 2, 页码 -

出版社

CURRENT MEDICINE GROUP
DOI: 10.1007/s11882-013-0413-5

关键词

Common cold; Prevention; Cure; Rhinovirus; Upper respiratory tract infections; Antiviral therapy; Vaccines; Influenza; RSV; Molecular diagnosis; Management; Passive immunization; Vaccination

资金

  1. Merck, Sharp Dohme
  2. Nestle
  3. GlaxoSmithKline
  4. Novartis
  5. Uriach
  6. Allergopharma
  7. Stallergen
  8. Meda

向作者/读者索取更多资源

The common cold is the most frequent, although generally mild, human disease. Human Rhinoviruses are the prevalent causative agents, but other viruses are also implicated. Being so common, viral colds, have significant implications on public health and quality of life, but may also be life-threatening for vulnerable groups of patients. Specific diagnosis and treatment of the common cold still remain unmet needs. Molecular diagnostic techniques allow specific detection of known pathogens as well as the identification of newly emerging viruses. Although a number of medications or natural treatments have been shown to have some effect, either on the number or on the severity of common colds, no single agent is considerably effective. Virus-specific management remains in most cases a challenging potential as many factors have to be taken into account, including the diversity of the viral genomes, the heterogeneity of affected individuals, as well as the complexity of this long standing host-virus relationship.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据